Oct 18, 2020 by Brian Orelli, PhDHere Are the Treatments President Trump Received for COVID-19, None of Which Are FDA "Approved"There's a difference between an FDA approval and an emergency use authorization.
Oct 15, 2020 by Brian Orelli, PhDHere's Why Anavex Life Sciences Jumped Higher TodayThe biotech's drug appears to help patients with Parkinson's disease dementia.
Oct 12, 2020 by Brian Orelli, PhDReport: Johnson & Johnson Coronavirus Vaccine Study Paused Due To Participant's Unexplained IllnessWith many unknowns, it's undetermined how the pause will impact the vaccine candidate's progress.
Oct 12, 2020 by Brian Orelli, PhDSorrento Therapeutics Adds Another COVID-19 Treatment to Its PipelineThe company's pipeline is large. Its list of FDA-authorized drugs is nonexistent.
Oct 11, 2020 by Brian Orelli, PhD3 Reasons Pfizer and BioNTech Will Have Coronavirus Vaccine Data Before ModernaDifferent clinical trial designs gives the duo an advantage, but coming in first isn't the end goal for vaccine makers.
Oct 9, 2020 by Brian Orelli, PhDAstraZeneca Secures $486 Million From U.S. Government for Coronavirus Antibody CocktailThe company plans to start phase 3 studies shortly.
Oct 8, 2020 by Brian Orelli, PhDModerna Doesn't Plan to Enforce Coronavirus Vaccine Patents During PandemicThe biotech is in a no-win situation.
Oct 6, 2020 by Brian Orelli, PhDExpect Pfizer/BioNTech and Moderna Coronavirus Vaccine Data Readouts in November-December, U.S. Vaccine Program Head SaysThat's a slight delay from the companies' best-case scenarios.
Oct 6, 2020 by Brian Orelli, PhDHere's Why BioNTech's Stock Price Jumped TodayA quicker EU approval for its coronavirus vaccine candidate could be in the cards.
Oct 5, 2020 by Brian Orelli, PhDPfizer and BioNTech Have Enrolled 83% of Their Up-Sized Coronavirus Vaccine TrialThe partners may not complete enrollment before Moderna, but they do have a lead in one critical enrollment measurement.
Oct 2, 2020 by Brian Orelli, PhDCanada Begins Reviewing AstraZeneca's Coronavirus Vaccine, U.S. Study Still Not RestartedThe rolling review should help the pharma get its vaccine approved quicker.
Sep 30, 2020 by Brian Orelli, PhD17 Reasons to Be Excited About Sorrento Therapeutics and 1 Big Reason to Be Very WorriedThe coronavirus could be the biotech's make-or-break event.
Sep 27, 2020 by Brian Orelli, PhDIf You Invested $1,000 in Inovio Pharmaceuticals in January, This Is How Much You'd Have NowThe number is rather shocking considering how much potential the biotech had at the time.
Sep 23, 2020 by Brian Orelli, PhDJohnson & Johnson Starts Late-Stage Coronavirus Vaccine Clinical TrialThe phase 3 study of JNJ-78436735, which will enroll 60,000 participants, is underway.
Sep 23, 2020 by Brian Orelli, PhDGood News for GoodRx's IPO: Drug Prices Are Rising FastThe new company makes money from its customers saving money.
Sep 17, 2020 by Brian Orelli, PhDAbbott Launches World's First Glucose Monitor for AthletesIt's not just for people with diabetes anymore.
Sep 17, 2020 by Brian Orelli, PhDBeyond Coronavirus: Moderna Teams Up With Vertex on Cystic Fibrosis TherapyThis is the companies' second project to tackle the lung disease.
Sep 17, 2020 by Brian Orelli, PhDBioNTech Buys a Plant to Manufacture Its Coronavirus VaccineThe plant can produce up to 750 million doses per year.
Sep 16, 2020 by Brian Orelli, PhDFluidigm's Saliva Coronavirus Test Being Run by 2 Certified LabsThe labs are each processing three-thousand tests per day.
Sep 16, 2020 by Brian Orelli, PhDCoronavirus Vaccine Trial Adverse Event Was Probably Unrelated to TreatmentThe paused clinical trial has already resumed.
